Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 20/20 | 0.43 |
| ▸ | PARP1 | P09874 | 20/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 20/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20954788 | 0.89 | TNKS (0.51) | TNKSPARP1TNKS2 | |
| SCHEMBL20954967 | 0.77 | POLB (0.40) | TNKSPARP1TNKS2 | |
| SCHEMBL26018017 | 0.71 | TNKS (0.48) | TNKSPARP1TNKS2 | |
| SCHEMBL20955537 | 0.70 | TNKS (0.34) | TNKSPARP1TNKS2 | |
| SCHEMBL18058753 | 0.67 | TNKS (0.65) | TNKSPARP1TNKS2 | |
| SCHEMBL16701424 | 0.66 | TNKS (0.61) | TNKSPARP1TNKS2 | |
| SCHEMBL3425926 | 0.65 | HPGD (0.53) | TNKSPARP1TNKS2 | |
| SCHEMBL18689727 | 0.65 | HPGD (0.50) | TNKSPARP1TNKS2 | |
| SCHEMBL22058384 | 0.65 | HRH4 (0.31) | TNKSPARP1TNKS2 | |
| SCHEMBL26026675 | 0.63 | PARP1 (0.42) | TNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | TNKS 3604/4885PARP1 1705/4885TNKS2 3815/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | TNKS 3690/4885PARP1 1906/4885TNKS2 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.